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Abstract
Since the first attempts in the 1970s to isolate cerebral microvessel endothelial cells (CECs) in order to model the
blood–brain barrier (BBB) in vitro, the need for a human BBB model that closely mimics the in vivo phenotype and
is reproducible and easy to grow, has been widely recognized by cerebrovascular researchers in both academia and
industry. While primary human CECs would ideally be the model of choice, the paucity of available fresh human
cerebral tissue makes wide-scale studies impractical. The brain microvascular endothelial cell line hCMEC/D3
represents one such model of the human BBB that can be easily grown and is amenable to cellular and molecular
studies on pathological and drug transport mechanisms with relevance to the central nervous system (CNS).
Indeed, since the development of this cell line in 2005 over 100 studies on different aspects of cerebral endothelial
biology and pharmacology have been published. Here we review the suitability of this cell line as a human BBB
model for pathogenic and drug transport studies and we critically consider its advantages and limitations.
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Review
Derivation and selection of hCMEC/D3 cells
The hCMEC/D3 cell line was derived from human tem-
poral lobe microvessels isolated from tissue excised during
surgery for control of epilepsy. The primary isolate was
enriched in CECs. In the first passage, cells were sequen-
tially immortalized by lentiviral vector transduction with
the catalytic subunit of human telomerase (hTERT) and
SV40 large T antigen, following which CEC were selectively
isolated by limited dilution cloning, and clones were exten-
sively characterized for brain endothelial phenotype [1].
The hCMEC/D3 cells form a contact-inhibited mono-
layer of elongated cells on collagen type I or type IV.
They do not show adhesion-independent growth in soft
agar but form capillary structures in Matrigel, a charac-
teristic property of cultured endothelium. They were
reported to have an apparently normal diploid human
karyotype [1], although a high-resolution multicolor
fluorescence in situ hybridization (FISH) approach re-
vealed a more complex karyotype at high passages than
initially thought [2]. In addition, they stain positively for
endothelial markers including CD34, CD31, CD40,
CD105, CD144 (VE-cadherin) and von Willebrand fac-
tor, but not for CD36, which is absent from brain endo-
thelium. They maintain stable growth and endothelial
marker characteristics, at least until the 35th passage.
The ‘transport barrier’ in hCMEC/D3 cells
Optimal culture conditions are essential for a brain
endothelial phenotype with mature adherens junction
(AJ) and tight junction (TJ) protein expression and a
strong permeability barrier function. Full differentiation
associated with expression of CEC markers like TJ pro-
teins requires cellular quiescence, achieved either by re-
moval of key growth factors and/or by exposing cells to
shear stress under flow (see below). Substrates for cell
growth may also contribute to differentiation. For ex-
ample, hCMEC/D3 monolayers display five-fold higher
concentrations of TJ proteins on transwell filters than
on plastic coverslips; in the same vein, we shall describe
below the hCMEC/D3 response to activation of Wnt/
β- catenin signaling, known to induce BBB formation du-
ring fetal development.
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Expression of junctional proteins
In the context of endothelial cell junctions, hCMEC/D3
cells are positive for junction-associated Ig-like proteins
such as PECAM-1 and JAM-A, for AJ and TJ structural
proteins such as VE-cadherin, claudin-3,-5 and occludin
as well as for scaffolding proteins such as beta catenin
and zonula occludens (ZO)-proteins-1 and 2 [1,3]. The
small G-protein Gαi2, suggested as a TJ-associated pro-
tein, was indeed identified as a partner of claudin-5 and
its presence was necessary for TJ formation in hCMEC/
D3 cells [4]. Expression of claudins and occludin at
intercellular junctions is best observed when the cells
are confluent, treated with anti-inflammatory steroids
such as hydrocortisone, anti-oxidant agents such as res-
veratrol, or the Wnt/β-catenin signaling activator, lith-
ium chloride (LiCl). The Wnt/β-catenin pathway acts in
hCMEC/D3 cells to induce/enhance the BBB phenotype
by increasing expression of claudins as demonstrated in
primary mouse CECs [5]. Similarly, all growth factors,
particularly vascular endothelial growth factor (VEGF),
should be removed from the culture medium with the
exception of basic fibroblast growth factor (bFGF) to en-
hance expression of junctional proteins. The hCMEC/
D3 cells express other newly identified junctional pro-
teins such as annexins-1 and -2, which also appear to be
important for maintenance of TJ integrity [6].
Comparison of transcriptional profiles of hCMEC/D3
cells and primary human CEC with freshly isolated
mouse CEC confirmed the expression by hCMEC/D3
cells of a substantial number of genes expressed by brain
endothelium, but showed lower expression of claudin-5,
occludin, JAM-2, glut-1 and the insulin receptor [7]. The
authors concluded that in order to attain a mature brain
endothelial phenotype, other cell types present in the
neurovascular unit (e.g. astrocytes, pericytes) regulate gene
expression by CEC, suggesting that a more complex
in vitro model might be required to fully mimic the BBB.
Alternatively, in line with the aforementioned differentiat-
ing action of the Wnt/β-catenin pathway, complementing
the hCMEC/D3 culture medium with astrocyte- and/or
pericyte-derived soluble factors might be sufficient for
further differentiation towards a BBB phenotype.
Restricted permeability to paracellular tracers
Monolayers of hCMEC/D3 show restricted permeability
to lucifer yellow (LY: a low molecular weight paracellular
diffusion marker) and to many hydrophobic and hydro-
philic low molecular weight drugs which correlate with
in vivo permeability coefficients as demonstrated by
Weksler et al [1] and confirmed by Poller et al [8]. They
also show a restricted permeability to low and high mo-
lecular weight dextrans that is similar to primary CECs
and lower than non-cerebral endothelium (e.g. human
umbilical vein endothelial cells, HUVECs), particularly
under conditions of flow [9]. Indeed, for compounds of
MW>4000, the permeability profile is very similar to
that of bovine and porcine CECs, hitherto the best cha-
racterized in vitro BBB models. As discussed above for
TJ protein expression, the permeability barrier function
is maximized in the presence of LiCl and corticosteroids
(or resveratrol): in these conditions, the permeability coef-
ficient (Pe) for LY, is: 1.55 +/- 0.16 10-3 cm/min. For com-
parison, Pe values for 4 kDa- and 70 kDa-dextrans are:
0.72 +/- 0.07 10-3 cm/min and 0.09 +/- 0.01 10-3 cm/min,
respectively.
Conversely, stress conditions and extracellular stimuli
have been shown to increase paracellular permeability of
hCMEC/D3 cells via signaling pathways such as JNK, PKC
or NFκB. These include mannitol treatment, oxygen and
glucose deprivation (OGD) and pro-inflammatory cyto-
kines such as TNFα and chemokines such as CCL2.
Cowan et al [10] examined the effects of OGD under
static conditions in hCMEC/D3 cells. They observed a re-
versible increase in monolayer permeability to dextran
after 1 h of OGD without cytotoxicity, but permanent
changes in monolayer permeability and marked cytotox-
icity after 12-24 h. The acute permeability changes in-
volved the generation of nitric oxide and could be
prevented by blocking inducible nitric oxide synthase.
Other studies have demonstrated that cytokines/chemo-
kines increase the paracellular permeability of hCMEC/D3
cells to dextrans via different mechanisms [11]. With pro-
inflammatory stimuli, ZO-1, occludin and claudin-5 ex-
pression levels are decreased [11,12], whereas JAM-A
translocates away from tight junctions, without any ex-
pression changes [13]. The chemokine CCL2, which is ele-
vated during CNS inflammation and is associated with
endothelial dysfunction, transiently induces Src-dependent
disruption of hCMEC/D3 AJs, translocation of β-catenin
from the AJ to PECAM-1, and increases surface loca-
lization of PECAM-1 [14].
In brief, these studies illustrate the usefulness of the
hCMEC/D3 model for unraveling the regulatory mecha-
nisms of junctional integrity and BBB permeability in
pathological conditions (for a review see [15]).
Transendothelial electrical resistance (TEER)
Although the TEER of human cerebral microvessels has
not been directly determined, it is widely accepted that
mammalian systems such as the rat show high TEER
values well above 1,000 Ω·cm2, a characteristic of the
BBB in vivo [16]. However, TEER values above 1,000
Ω·cm2 are difficult to achieve in cultured CEC in vitro
and this is particularly true for cell lines compared
to primary cultures. Under static culture conditions,
hCMEC/D3 monolayers develop only a low to medium-
level TEER (around 30-50 Ω·cm2) in various reports.
Interestingly, higher TEER values close to 300 Ω·cm2,
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were observed in the presence of hydrocortisone, prob-
ably due to the modulatory activity of corticosteroids on
the expression of TJ proteins such as occludin and
claudin-5 [12]. Another strategy targeted at increasing
TEER values in hCMEC/D3 cells has involved co-culture
with other cell types forming the neurovascular unit,
as suggested above. In a recent paper, co-culture of
hCMEC/D3 cells with astrocytes from different brain re-
gions evoked a significant TEER increase from 30 to
over 60 Ω·cm2 [17]. In both monocultures and co-
cultures of hCMEC/D3 with astrocytes, TEER values
increased from baseline over an interval of 5 days, pre-
sumably due to TJ maturation with time. By far the most
promising method to increase hCMEC/D3 cell TEER
values has been exposure to flow-based shear stress. In-
deed, in hCMEC/D3 monolayers subjected to pulsatile
flow after seeding in a capillary cartridge system, the
TEER was reported to rise to 1000-1200 Ω·cm2, then to
rapidly drop following flow cessation [8]. Co-culture
with astrocytes did not induce any further increases in
TEER values in this flow-based model suggesting that, at
least in vitro, shear stress may be a more critical factor
in inducing a mature barrier phenotype than interactions
with other cell types.
The ‘transport’ barrier in hCMEC/D3 cells
Efflux and trans-cellular transport systems expressed by
CECs are key factors for studying and predicting interac-
tions of drugs at the BBB; an adequate pattern of trans-
porter expression thus constitutes a prerequisite for
suitable in vitro human BBB models.
Expression, function and regulation of ABC transporters
hCMEC/D3 cells express functional efflux transporters
(known as ABC transporters because they contain ATP-
binding cassette(s) for active transport), typical for brain
endothelium, as observed in freshly isolated human
brain microvessels: these include P-glycoprotein (P-gp or
MDR1 or ABCB1), breast cancer resistance protein
(BCRP or ABCG2), and multidrug resistance-associated
proteins (MRP) -4 and -5 (or ABCC4 and 5) [18]. In
addition, hCMEC/D3 cells express MRP-1, as previously
reported with primary human brain endothelial cells in
culture, strongly suggesting that in vitro culturing may
non-physiologically induce the expression of this gene
[18]. Protein expression of P-gp/MDR1, MRP4, BCRP by
hCMEC/D3 cells (grown on collagen-coated dishes) was
further assessed by quantitative proteomic analysis [19],
whereas no expression of P-gp/MDR1 was detected in
HUVECs, used as reference non-brain EC. Interestingly,
expression levels of P-gp, BCRP and MRP4 were similar
in hCMEC/D3 cells and in isolated human brain
microvessels [19]. Moreover, these key transporters are
functional in hCMEC/D3 cells as efflux transporter
inhibition studies invariably leads to elevated intracellu-
lar levels of their substrates [1,8,18]. In addition, P-gp
expression is polarized to the apical membrane as previ-
ously demonstrated in situ in human brain microvessels
and appears to be stable for at least 40 passages [20].
ABC transporter activity and/or expression levels may
be modulated by extracellular stimuli. For example,
Poller et al [21] noted that P-gp activity was not altered
by TNF-α treatment, although P-gp expression levels in-
creased after treatment. However, it is noteworthy that
apparent increases in P-gp expression have been found
in some cases to be due to selection of high Pgp-
expressing hCMEC/D3 cells, for example, after exposure
to potentially cytotoxic agents, and so may not reflect
real increases in P-gp expression [22]. Substrates for
P-gp can increase its level of expression and activity as
demonstrated in hCMEC/D3 cells exposed to the HIV-1
protease inhibitors ritonavir and atazanavir, both sub-
strates for P-gp. Inhibition of P-gp (but not of MRP-1)
increased transport of these protease inhibitors. These
drugs bind the xenobiotic receptor PXR which likely acts
as a transcription factor for P-gp [23]. Concern about
P-gp up-regulation during long-term administration of
antiretroviral therapy, thus possibly blocking brain entry
of these protease inhibitors (as well as of other thera-
peutic drugs) suggests that the hCMEC/D3 model may
prove useful in designing newer antiretroviral therapies
that use other means of crossing the BBB. Of interest,
HIV-1 Tat can also lead to up-regulation of P-gp expres-
sion and hence contribute to decreased entry of anti-
retroviral therapy into the CNS [24].
In contrast to P-gp, BCRP expression and activity are
decreased by inflammatory cytokines, in particular IL-1β
and TNFα [21]. Conversely, agonists of the peroxisome
proliferator-activated receptor alpha (PPARα) up-
regulate BCRP in hCMEC/D3 cells, and can significantly
decrease accumulation of drugs that are BCRP sub-
strates (e.g. mitoxantrone). PPARα antagonists down-
regulate BCRP in these CECs [25] suggesting new
targeting strategies for either improving drug brain bio-
availability or increasing neuroprotection. Along the
same lines, BCRP was shown, using hCMEC/D3 cells,
to mediate the transport of nifurtimox, an anti-
trypanosomal drug [26]. These observations indicate that
BCRP inhibitors potentially could improve the activity of
anti-trypanosomal drugs and confirm that the hCMEC/
D3 model is appropriate to test novel drugs.
Influx transporters of the solute carrier family and
receptor-mediated transcytosis
Brain endothelium is known to express a large number of
membrane receptors and transporters that specifically con-
trol the blood-to-brain transport of nutrients, including in-
sulin, transferrin and LDL receptors as well as glucose,
Weksler et al. Fluids and Barriers of the CNS 2013, 10:16 Page 3 of 10
http://www.fluidsbarrierscns.com/content/10/1/16
amino-acids and organic ion transporters, all members of
the solute carrier family (SLC) of transporters. Accordingly,
hCMEC/D3 cells were tested for expression of these recep-
tors and transporters by immunochemical analysis, RT-
PCR and/or quantitative proteomic analysis. First, they
were shown to express at a high level the glucose trans-
porter Glut-1 and the transferrin receptor. Indeed, Glut-1
expression was found by quantitative proteomic analysis to
be 15-fold higher in hCMEC/D3 cells than in HUVECs
and similar to that of human brain microvessels [19]. In-
flux transporters such as the cation transporter OCT-1,
and to a lesser extent OCT-2 and -3 are expressed and
functional in hCMEC/D3 cells. OCT-1 is responsible for
CEC uptake of the antiepileptic drug lamotrigine, a process
blocked by the selective inhibitor prazosin [27]. Also,
hCMEC/D3 cells express the neutral and cationic amino
acid transporter (ATB0,+), which may be involved in the
brain uptake of the anti-influenza compounds amantadine
and rimantadine [28]. In addition, Carl et al [29] reported
the expression by hCMEC/D3 cells of the monocar-
boxylate transporters SLC16A1 and SLC16A3 (MCT1 and
MCT3), while little or no expression of SLC16A2 (MCT2)
was noted. In agreement with these data, a high level of
SLC16A1 expression at the protein level was detected by
quantitative proteomic analysis of hCMEC/D3 cell extracts
[19]. Regarding the proton-coupled oligopeptide trans-
porter superfamily (POT, SLC15A) transporters, Carl et al
also reported that hCMEC/D3 cells express both hPHT1
and hPHT2, while little to no expression of either hPepT1
or hPepT2 was observed, in line with previous data in the
human BBB in vivo [29].
The ‘metabolic’ barrier in hCMEC/D3 cells
The activity of drug-metabolizing enzymes, especially
phase 1 cytochromes P450 (CYPs), might also indirectly
control the cerebral uptake of compounds from the blood
[30]. The aryl hydrocarbon nuclear receptor (AhR) was
detected in hCMEC/D3 cells and dioxin (a ligand of AhR)
treatment increased cytochromes P450 CYP1A1 and
CYP1B1 over 20-fold [18]. Interestingly, CYP1B1 was pre-
viously identified as the major CYP in freshly isolated
human brain microvessels [31], suggesting that the
hCMEC/D3 model may be well adapted for further studies
regarding the regulatory mechanisms of CYP1B1 expres-
sion by brain endothelium.
Drug vectorization and trans-cellular transport
Numerous studies of liposomes and nanoparticles as ve-
hicles for crossing the BBB while avoiding efflux trans-
porters have utilized hCMEC/D3 cells. For example,
Chattopadhyay et al [32] showed that solid lipid nano-
particles encapsulating atazanavir can circumvent P-gp
efflux activity that usually limits uptake of the drug.
Markoutsa et al [33] tested immunoliposomes bearing
both a monoclonal antibody to the transferrin receptor
(OX-28) and another isotype-matched monoclonal anti-
body linked to the lipid particles via a biotin-streptavidin
technique, and showed that these structures were well
taken up and transcytosed. These authors concluded
that the hCMEC/D3 model was useful for particle
transport studies. More recently, a combination of LDL
receptor-targeted liposome-encapsulated doxorubicin
and statins, known to increase LDL receptor expression,
was shown to increase the drug delivery across hCMEC/
D3 monolayers [34], suggesting a new concept of drug
delivery to the brain. The toxicity of gold nanoparticles
was evaluated in hCMEC/D3 compared to epithelial
cells [35]. Sodium citrate on the particle surface but not
particle size contributed to impaired viability and prolif-
eration of endothelial cells, which internalized fewer
nanoparticles than epithelial cells.
Single chain camelid antibody VHH fragments with
anti-glial fibrillary protein (GFP) activity as well as fu-
sion protein VHH- GFP were able to cross hCMEC/D3
monolayers as “fluobodies” [36]. Indeed, the same VHH
crossed the BBB in vivo in mice and localized to astro-
cytes, showing for the first time that an antibody was
efficiently able to penetrate the BBB and target resident
cells in the brain.
Interactions of immune cells with hCMEC/D3 cells
Although the CNS was originally considered an “immune-
privileged site” because of the presence of the BBB and the
apparent absence of lymphatic drainage, it is now well
recognized that activated lymphocytes and monocytes
do infiltrate the CNS by crossing the BBB and that
neuroimmune diseases such as multiple sclerosis are char-
acterized by massive perivascular infiltrates around brain
microvessels. The hCMEC/D3 cell line provides a useful
model for deciphering the modes of interactions between
human brain endothelium and activated immune cells.
Response of hCMEC/D3 cells to inflammatory mediators
The hCMEC/D3 cells respond to inflammatory stimuli
by increasing paracellular permeability to tracers (see
previous section) and are able to support adhesion and
migration of leukocytes by increased expression of adhe-
sion proteins like ICAM-1 and VCAM-1 [1]. They ex-
press functional cytokine and chemokine receptors such
as TNFR1 and 2, IFNGR1 and CXCR1-5 and CCR3-6
[1,37]. Indeed, Fasler-Kan et al [38] demonstrated TNFα
activation of NFκB signaling, whereas interferon gamma
(IFNγ induced activation of JAK/STAT signaling path-
ways, and upregulated MHC Class I. In addition, secre-
tion of chemokines by CECs may be an additional
mechanism for modulating leukocyte extravasation. Fur-
thermore, hCMEC/D3 cells secrete chemokines in a
similar fashion to primary human brain endothelium
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both under basal conditions (CCL2 and CXCL8)
or following stimulation by cytokines (CCL5, CXCL10,
CX3CL1 or fractalkine) [39,40].
Leukocyte adhesion to and transmigration across hCMEC/
D3 cells
Monocytes adhere to activated hCMEC/D3 cells and mi-
grate across the monolayer. The interaction between hu-
man monocytes and hCMEC/D3 cells involves the
generation of reactive oxygen species (ROS), release of
tissue-plasminogen activator (tPA) from the endothelial
cells and a subsequent increase in permeability of the
endothelial monolayer to large molecules (>150 kDa).
Degradation of occludin appears to mediate the opening
of endothelial-endothelial TJs [41]. Blocking the ERK1/2
pathway can partly reverse the monocyte-induced open-
ing of monolayer TJs and impede occludin degradation.
The same mechanism as demonstrated in the hCMEC/
D3 model underlies brain changes in experimental auto-
immune encephalomyelitis in the rat, a model of mul-
tiple sclerosis, as well as in rat monocytes and rat brain
endothelial cells in vitro, suggesting that it is a general-
ized mechanism and may be pertinent in multiple scler-
osis pathology. The same authors recently reported that
a modulator of the sphingosine-1-phosphate (S1P) re-
ceptor, known to reduce inflammatory lesions in mul-
tiple sclerosis (FTY720P or GilenyaW), actually maintains
hCMEC/D3 cells in a state of immune quiescence asso-
ciated with decreased transmigration of monocytes [42].
This result further validates the hCMEC/D3 model for
investigating the regulatory mechanisms of inflammation
at the BBB.
Monocyte adhesion to hCMEC/D3 cells is enhanced
by endothelial treatment with TNFα or IFNγ and can be
inhibited by antibodies to the integrin VLA-4. A role for
the junction-associated prion protein PrPC in monocyte
transmigration through brain endothelial cells was dem-
onstrated with hCMEC/D3 cells, using either the U937
monocytic cell line or fresh primary blood monocytes:
antibodies to the prion protein inhibited monocyte
transmigration across the endothelial layer, whereas
anti-PECAM 1 antibodies had no effect [43]. This inhib-
ition was also observed with mouse primary brain EC
and with a rat brain endothelial cell line, suggesting, as
above, a mechanism common to brain endothelium
from several species.
Bahbouhi et al [44] used hCMEC/D3 cells as a BBB
model to compare adhesion and transmigration across
CEC by peripheral blood mononuclear cells (PMBC) or
purified T cells from multiple sclerosis patients versus
PBMC or T cells from healthy individuals. They ob-
served that PBMC migration is dependent on PSGL-1
and LFA-1 present on the PBMC. Both CD4+ and CD8+
T cells utilize these ligands to adhere to brain
endothelium via P-selectin and VLA-4, respectively, and
adherence can be blocked by anti-ligand antibodies. In
multiple sclerosis, the frequency of CD4+ T cells that
are PSGL-1+ is significantly greater than in healthy indi-
viduals; CD8+ cell populations were similar in both MS
patients and controls. Transmigration of PBMC from
multiple sclerosis individuals was enhanced across both
resting and TNFα-activated hCMEC/D3 cells. The abso-
lute transmigration was much greater across TNFα-acti-
vated hCMEC/D3 cells. Interestingly, PMBC from
individuals treated with IFNβ a widely used first-line
treatment of multiple sclerosis) had lower rates of trans-
migration and demonstrated lower LFA-1 levels.
Whether human neutrophils induce permeability
changes in brain endothelium was studied by Joice et al
[45] using hCMEC/D3 monolayers. This study was
undertaken to understand whether neutrophil accumula-
tion contributes to vasogenic edema in stroke. Untreated
neutrophils applied to the hCMEC/D3 monolayers for
30 min actually decreased baseline permeability to low
molecular weight (4 kDa) dextran by 53%, whereas
neutrophils preactivated with TNFα, LTB4 or PMA
(treatments that induced marked release of ROS) had no
effect on baseline permeability. The authors then
showed, in rats injected intracerebrally with human neu-
trophils, that very similar changes in brain vascular
edema were seen. The authors concluded that the
hCMEC/D3 model was useful in evaluating potential
contributions to vasogenic edema.
The hCMEC/D3 model for investigating Host-
Pathogen Interactions
The hCMEC/D3 cell line has been widely used to model
brain endothelium for investigating the molecular mecha-
nisms of its interaction with and response to multiple hu-
man pathogens (viruses, fungi, bacteria and parasites)
known to affect the CNS. Below are mentioned some of
the most exciting results reported in this field.
Retroviruses
Studies related to retroviral infection have concerned
two pathogens, HTLV-1 and HIV-1. HTLV-1 infects
hCMEC/D3 cells via their receptors for viral entry,
Glut-1 and neuropilin-1, an observation that has been
confirmed in situ in necropsy material from patients
with TSP/HAM (tropical spastic paraparesis/human
T-lymphotropic virus type-I-associated myelopathy) [3].
CEC infection leads to increases in paracellular perme-
ability and TJ disorganization, probably via expression of
the viral protein Tax. An additional mechanism leading
to BBB disruption is via secretion of TNFα and IL1α by
HTLV-1 infected T cells [46].
In the context of HIV-1, studies on hCMEC/D3 cells
have focused on 1) mechanistic studies on HIV-1-
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induced BBB breakdown or 2) a model to investigate
effects of anti-HIV therapeutics, particularly protease in-
hibitors, on BBB function (see previous section). For
mechanistic studies, it has been demonstrated that HIV-
1 and/or Tat protein induces disruption of claudin-5 and
increases permeability of hCMEC/D3 cells in a similar
fashion to effects on primary rodent BECs [47]. Tat-
induced delocalization of ZO-1 from the membrane into
the nucleus is mediated by Rho signaling and CREB [48].
In addition, Tat induces hCMEC/D3 cells into an acti-
vated inflammatory state by inducing increased expres-
sion of IL-1β, E-selectin, CCL-2, and IL-6 [49], an effect
that is attenuated by PPARα and PPARγ agonists [50]
via matrix metalloproteases [51]. As a result, HIV-1-
infected monocytes, or Tat protein itself, have been
shown to increase ICAM-1 expression and to favor
transmigration of the infected monocytes across
hCMEC/D3 cells by a mechanism that involved NFκB-
induced release of MMP-9 [52].
HIV Tat also induces amyloid beta (Aβ) peptide accu-
mulation in hCMEC/D3 cells which may contribute to
its effect on BBB function [53]. Aβ accumulation and
Tat-induced barrier dysfunction are lipid raft- and
caveolae-dependent and involve caveolae-associated Ras
signaling [54,55]. As mentioned above, Tat can also lead
to up-regulation of P-gp expression and hence contrib-
ute to decreased entry of antiretroviral therapy into the
brain [24].
Cryptococcus
Adhesion to and penetration across a monolayer of
hCMEC/D3 cells by the fungal pathogen Cryptococcus
neoformans was demonstrated by Vu et al [56], who
found that a large polysaccharide capsule on the fungus
plus CD44, the hyaluronic acid receptor present on the
hCMEC/D3 cells, were both important for the adher-
ence of fungal particles to endothelial cells. Upon adher-
ence of Cryptococci, the endothelial cells developed
microvilli that attached to the fungi and appeared to aid
in their transcytosis. Conversely, removal of hyaluronic
acid or use of non-encapsulated organisms blocked ad-
herence. The authors pointed out that although the
TEER of the monolayers was low—about half that of pri-
mary brain endothelial cells—it was not further lowered
by the adherence of Cryptoccocci and appeared to con-
stitute a genuine barrier.
Meningococcus
Although meninogocci (Neisseria meningitidis) are com-
monly carried in the nasal and oral mucosa of humans,
direct meningococcal infection of the brain, a devastat-
ing illness, is fortunately rare. How meningococci enter
the brain has long been poorly understood, but hCMEC/
D3 cells used as a model of the BBB have importantly
contributed to the elucidation of this mechanism. Adhe-
sion of meningococci on hCMEC/D3 monolayers in-
duces translocation of multiple endothelial membrane
proteins, including ezrin, moesin, and actin to form
honeycomb cortical plaques beneath the meningococcal
colonies. Coureuil et al [57] observed that type IV pili
present on pathogenic meninogocci recruited to the site
of bacterial colonies the Par3/Par6/PKCζ endothelial po-
larity complex. This complex normally plays a pivotal
role in the establishment of eukaryotic cell polarity and
governs the formation of intercellular junctions; its
translocation to these cortical plaques led to the forma-
tion of ectopic intercellular junctional domains at the
sites of bacteria-endothelial cell interactions and de-
pleted junctional proteins at endothelial cell-cell inter-
faces. This response of hCMEC/D3 cells resulted in the
opening of intercellular junctions, thus permitting para-
cellular bacterial infiltration across the endothelial bar-
rier. Coureuil et al further [58] explored the hCMEC/D3
model to ascertain the signaling pathway that recruits
the cortical plaques to meningococcal colony sites. They
elegantly demonstrated that meningococci “hijack” an-
other endothelial physiological pathway through activa-
tion of β-adrenergic receptors by their Type IV pili,
followed by activation of the scaffolding protein β-
arrestin and the tyrosine kinase Src. Activation of this
pathway favors endocytosis of phosphorylated VE-
cadherin, a normal component of TJs, further opening
up endothelial TJs. Of note, these authors recently
reported that this pathway is also used by non-brain
microvascular endothelial cells, but is clearly distinct
from that used by epithelial cells [59].
Plasmodium falciparum
Cerebral malaria, a common complication of Plasmo-
dium falciparum infection particularly in children, is
one of the most severe and often lethal manifestations of
this common tropical disease. Induction of cerebral
edema during cerebral malaria is among the most feared
complications of this disease, yet the mechanisms are
not well understood. The hCMEC/D3 cell line has pro-
vided an excellent in vitro model for studying the de-
tailed interactions between P. falciparum parasites and
brain endothelium. Jambou et al [60] evaluated the
mechanism of P. falciparum-parasitized erythrocyte ad-
hesion to hCMEC/D3 cells and showed for the first time
that this process involved trogocytosis, the transfer of
membrane material from one cell (malarial antigens on
parasitized erythrocyte) to another cell (endothelial cell),
followed by ingestion of the entire parasitized erythro-
cyte. These authors compared the hCMEC/D3 cell line
with the HBEC-5i cell line and showed that the HBEC-
5i line displayed a more activated phenotype when un-
stimulated, expressing much higher levels of ICAM-1,
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an important receptor in the interaction between para-
sitized erythrocytes and brain endothelial cells [60].
Blocking ICAM-1 or TNFα activation of endothelial
cells prevented cytoadhesion of parasitized erythrocytes
and their ingestion. More recently, hCMEC/D3 cells
were used by Zougbede et al [61] to demonstrate that
P. falciparum-parasitized red blood cells could alter BBB
integrity also by a mechanism independent of cyto-
adhesion, namely, by induction of metabolic acidosis,
which also resulted in opening TJs in the hCMEC/D3
monolayer, a process which also would favor develop-
ment of cerebral edema.
The hCMEC/D3 model for investigating
neurodegenerative diseases
It is now well recognized that brain endothelium dysfunc-
tion likely contributes to the progression of several neuro-
degenerative diseases, initially considered as purely due to
neuronal alterations, like Alzheimer’s or Parkinson’s dis-
eases. The hCMEC/D3 model has been widely used to
study the toxic effects of Aβ peptides on brain microvas-
culature in the context of Alzheimer’s disease. Aβ 1-40,
the most abundant toxic Aβ peptide around blood vessels,
was shown to increase hCMEC/D3 monolayer permeabil-
ity, in the absence of cytotoxic effects, via the down-
regulation of the TJ protein occludin, without changing
levels of claudin-5 or ZO-1 [62]. The Aβ 1-40 effect on
permeability could be prevented by inhibiting JNK or
p38MAPK, suggesting that these signaling pathways rep-
resented a possible therapeutic target in the treatment of
Alzheimer’s disease.
Aβ peptides have been shown to decrease the activity
of efflux transporters in hCMEC/D3 cells [63]. Indeed,
when hCMEC/D3 cells were exposed to Aβ peptides,
P-gp mRNA and protein levels decreased through
down-modulation of the Wnt/β-catenin signaling path-
way (by decreasing β-catenin level and increasing DKK-
1, an endogenous Wnt signaling inhibitor). These
changes were reversed by administration of Wnt3a. The
effect was specific for P-gp, as MDR4 and BRCP were
not affected in these studies.
The hCMEC/D3 cell line was used to study cerebral
amyloid angiopathy (CAA), an age-associated hemor-
rhagic condition commonly found in sporadic as well as
some familial types of Alzheimer’s disease. Fossati et al
[64] observed that Aβ peptides induce caspase-mediated
mitochondrial dysfunction, then apoptosis in hCMEC/D3
cells; Aβ peptides bearing familial CAA mutations were
more toxic to CEC than wild type Aβ peptides. Apoptosis
of hCMEC/D3 cells was associated more with oligomeric
peptide forms than with amyloid fibrils, a finding consis-
tent with increasing evidence that oligomers of Aβ rather
than the precipitating fibers are the most neurotoxic form.
Similarly, hCMEC/D3 cells were used to evaluate the con-
tribution of metalloproteases to the pathogenesis of CAA
[65]. When hCMEC/D3 were exposed to Aβ peptides, the
cells increased both production and enzymatic activity of
MMP2 which in turn degraded Aβ peptides to Aβ 1-16
C-terminal fragments resulting in decreased CEC apop-
tosis. Conversely, silencing MMP-2 led to further Aβ 40/
42-induced mitochondrial dysfunction and increased apop-
tosis of hCMEC/D3 cells. Thus, MMP2 may represent a
potential vasoprotective and neuroprotective response of
the brain vasculature.
Finally, the hCMEC/D3 cell line has also been used to
investigate Aβ clearance mechanisms from the CNS to
prevent both neurotoxic and vasculotoxic effects. In-
deed, a first report on hCMEC/D3 cells showing that Aβ
is selectively effluxed when present on the luminal, but
not the abluminal side [66] has been also confirmed in
primary bovine CEC models [67] suggesting that P-gp
may act as a protective mechanism against plasma Aβ
but not participate in the clearance of brain Aβ although
its relevance in vivo remains to be determined.
Advantages and limitations of hCMEC/D3 cells
In summary, results from various laboratories worldwide
indicate that hCMEC/D3 cells retain the expression of
Table 1 Published immortalized human brain EC lines
Cell lines Immortalization procedure Phenotype/limitations TEER
(Ω.cm2)
LY/sucrose permeability
coefficient (10-3 cm/min)
Year
(first pub)
Ref.
BB19 HPV16 E6E7 Constitutive expression of VCAM-1,
CD36
nd 1.35 1996 [68,69]
HCEC SV40T No permeability characterization 40±8 nd 2000 [70]
HBEC-5i SV40T No expression of CD31 180±10 nd 2006 [71]
NKIM-6 HPV16 E6E7 No expression of claudin-5 or
occludin
100 nd 2007 [72]
HBMEC-3 SV40T No information available 245±8 nd 2009 [73]
TY08 Temperature-sensitive SV40T Low level of functional P-gp 37±5 Pe(inulin)=1.23 2010 [74]
HBMEC/
ciβ
Temperature-sensitive SV40T and
hTERT
Promising preliminary characterization nd 2.6±0.4 2012 [75]
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most transporters and receptors expressed in vivo at the
human BBB, including MDR1, BCRP, MRP4, transferrin
receptor, insulin receptor, Glut-1; they also express me-
tabolizing enzymes and TJ proteins, as expected.
Relatively few alternative models of the human BBB
have been proposed, either as primary human CEC or
cell lines. The following table (Table 1) summarizes
other human CEC lines that have been used within the
last decade. In contrast to the hCMEC/D3 cell line, most
of them have been only minimally characterized. This
strengthens the conclusion that the hCMEC/D3 cell line
constitutes a unique model for investigating the biology
of human brain endothelium.
However, a recent publication elegantly described the
preparation of human BBB ECs from induced pluripo-
tent stem (iPS) cells or embryonic stem (ES) cells [76].
Indeed, pure brain EC populations were isolated follow-
ing serial incubation of human iPS or ES cells first with
medium favoring neural differentiation and later with
medium favoring endothelial differentiation. These stem
cell-derived CECs grew as pure cultures, exhibited brain
TJ molecules and transporters and developed a high
TEER, significantly higher than hCMEC/D3 cells. Al-
though the reproducibility of this sophisticated approach
remains to be confirmed, these results demonstrate that
understanding the molecular mechanisms of BBB devel-
opment and regulation permits efficient modeling of the
human BBB in vitro. This new model displays excellent
barrier characteristics and may, in the future, constitute
for the pharmaceutical industry a key tool for investigat-
ing BBB permeability to candidate drugs.
Conclusion
To date, the main advantage of the hCMEC/D3 cell line
is that it represents a stable, easily grown and transfer-
able population of human microvascular CEC that stably
maintains a normal BBB phenotype. As illustrated above,
it appears particularly well adapted for drug uptake and
active transport studies, as well as for understanding the
brain endothelium response to various human pathogens
and inflammatory stimuli. Optimizing the TJ tightness of
hCMEC/D3 cell monolayers still remains a major chal-
lenge in order to provide an in vitro model that might
recapitulate all the characteristics of human BBB,
encompassing permeability restriction with appropriate
molecular exclusion and functional efflux and influx
transport systems. As suggested above, culture under
flow together with treatment with recently identified
BBB modulators may greatly help design strategies for
hCMEC/D3 optimization. The large network of labora-
tories currently working with this model worldwide
actually constitutes a major asset for achieving this
objective.
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